Data S1. Evaluation of Fluoxetine in Overall Survival of GBM Patients Using Electronic Medical Records from The IBM MarketScan Dataset

Name: Data S1. Evaluation of Fluoxetine in Overall Survival of GBM Patients Using Electronic Medical Records from The IBM MarketScan Dataset
Creator: Junfeng Bi
Published: 2021-09-29T06:56:56.751Z
Keywords: Glioblastoma Multiforme, Brain Cancer Survival

Bi, Junfeng; Khan, Atif; Rzhetsky, Andrey; Mischel, Paul

doi:10.17632/5gww3pgbj3.1

Data S1. Evaluation of Fluoxetine in Overall Survival of GBM Patients Using Electronic Medical Records from The IBM MarketScan Dataset

Published: 29 September 2021| Version 1 | DOI: 10.17632/5gww3pgbj3.1

Contributors:

Junfeng Bi, Atif Khan, Andrey Rzhetsky, Paul Mischel

Description

The potential therapeutic benefit of fluoxetine with standard of care treatment was evaluated in GBM patients cohort using electronic medical records from the IBM MarketScan Dataset (2003-2017). GBM Patients with two other SSRIs, citalopram and escitalopram, were used as controls. The dataset includes six figures: data S1 Figures 1-6 which provide more details of the data overview, data extraction pipeline, exclusion criteria, enrichment for GBM patients, statistical analyses, and results.

Data S1. Evaluation of Fluoxetine in Overall Survival of GBM Patients Using Electronic Medical Records from The IBM MarketScan Dataset

Description

Files

Categories

Licence